Conduit Pharmaceuticals Inc. (CDT)
USD 0.07
(-10.01%)
USD 0.07
(-10.01%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 5.56 Million | 3.16 Million | 3.17 Million |
| Selling, General and Administrative Expenses | 5.47 Million | 3.04 Million | 2.89 Million |
| Research and Development Expenses | 90 Thousand | 111 Thousand | 283 Thousand |
| Other Expenses | - | - | - |
| Cost and Expenses | 5.56 Million | 3.16 Million | 3.17 Million |
| Operating Income | -5.56 Million | -3.16 Million | -3.17 Million |
| Interest Expense | 211 Thousand | - | - |
| Income Tax Expense | -167.89 Thousand | 374.86 Thousand | 247.44 Thousand |
| Earnings before Tax | -535 Thousand | -4.88 Million | -3.65 Million |
| Net Income | -535 Thousand | -4.88 Million | -3.65 Million |
| Earnings Per Share Basic | -0.09 | -0.28 | -0.21 |
| Earnings Per Share Diluted | -0.09 | -0.28 | -0.21 |
| Weighted Average Shares Outstanding | 66.97 Million | 17.28 Million | 17.28 Million |
| Weighted Average Shares Outstanding (Diluted) | 67.89 Million | 17.28 Million | 17.28 Million |
| Gross Margin | - | - | - |
| EBIT Margin | - | - | - |
| Profit Margin | - | - | - |
| EBITDA | -324 Thousand | -1.43 Million | -4381.00 |
| Earnings Before Tax Margin | - | - | - |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 654.92 Million | 604.33 Million | 535.67 Million | - | - | - |
| Cost of Revenue | 410.92 Million | 377.53 Million | 334.07 Million | - | - | - |
| Gross Profit | 244 Million | 226.8 Million | 201.59 Million | - | - | - |
| Operating Expenses | 154.91 Million | 3.14 Million | 2.95 Million | 5.56 Million | 895 Thousand | 1.06 Million |
| Selling, General and Administrative Expenses | 126.97 Million | 3.11 Million | 2.82 Million | - | 805 Thousand | 1.06 Million |
| Research and Development Expenses | 27.94 Million | 25 Thousand | 128 Thousand | - | 90 Thousand | - |
| Other Expenses | - | -2.21 Million | -487 Thousand | - | -2.26 Million | 3.1 Million |
| Cost and Expenses | 565.83 Million | 3.14 Million | 2.95 Million | 5.56 Million | 895 Thousand | 1.06 Million |
| Operating Income | 75.34 Million | -3.14 Million | -2.95 Million | -5.56 Million | -895 Thousand | -1.06 Million |
| Interest Expense | -10.85 Million | 119 Thousand | 119 Thousand | 211 Thousand | 330 Thousand | 47 Thousand |
| Income Tax Expense | -11.09 Million | -11.09 Million | -8.36 Million | -167.89 Thousand | 300 Thousand | 47 Thousand |
| Earnings before Tax | 64.78 Million | -5.38 Million | -3.55 Million | -535 Thousand | 1.77 Million | 1.98 Million |
| Net Income | 53.69 Million | -5.38 Million | -3.57 Million | -535 Thousand | 1.77 Million | 1.98 Million |
| Earnings Per Share Basic | 1.32 | -0.07 | -0.05 | - | 0.02 | 0.03 |
| Earnings Per Share Diluted | 1.30 | -0.07 | -0.05 | - | -0.02 | 0.03 |
| Weighted Average Shares Outstanding | 40.79 Million | 73.85 Million | 73.82 Million | 66.97 Million | 73.82 Million | 65.41 Million |
| Weighted Average Shares Outstanding (Diluted) | 41.41 Million | 73.85 Million | 73.82 Million | 67.89 Million | 79.54 Million | 66.13 Million |
| Gross Margin | 0.37 | 0.38 | 0.38 | - | - | - |
| EBIT Margin | 0.12 | -0.01 | -0.01 | - | - | - |
| Profit Margin | 0.08 | -0.01 | -0.01 | - | - | - |
| EBITDA | 75.34 Million | -3.14 Million | -2.95 Million | - | 2.1 Million | 2.03 Million |
| Earnings Before Tax Margin | 0.12 | -0.01 | -0.01 | - | - | - |
0JUJ
LBTYB
SMTK
SPZ
8158
DSX